Ianalumab
Ianalumab is a human monoclonal antibody designed for the treatment of diseases that are mediated by the B cell activating factor (BAFF), such as systemic lupus erythematosus and Sjögren's syndrome. It was developed by Novartis.
Mechanism of action[edit]
Ianalumab works by binding to the B cell activating factor (BAFF), a protein that plays a key role in the survival and proliferation of B cells. By blocking BAFF, ianalumab reduces the number of B cells, which are thought to contribute to the development of autoimmune diseases.
Clinical trials[edit]
Ianalumab has been tested in several clinical trials. In a phase II trial for systemic lupus erythematosus, ianalumab showed a significant reduction in disease activity compared to placebo. A phase III trial is currently underway.
Side effects[edit]
The most common side effects of ianalumab include infections, headache, and nausea. Serious side effects can include severe infections and allergic reactions.
See also[edit]
- Monoclonal antibodies
- Systemic lupus erythematosus
- Sjögren's syndrome
- B cell activating factor
- Novartis
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
